Healthcare Business Review: Streamline Shares Soar, XOMA Begins Tests

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Shares of Streamline Health Solutions (NASDAQ:STRM) hit a new 52-week high Thursday morning, perhaps driven by new insider buying. The stocks are continuing their run of more than 210 percent which started early in May.

XOMA (NASDAQ:XOMA) reports that its partner, Servier, has initiated phase 3 clinical trials of Gevokizumab, which are aimed at testing the efficacy and safety of the medication in the treatment of patients suffering from Beh├žet’s Disease uveitis.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Life Technologies Corporation (NASDAQ:LIFE) wins FDA clearance for its OpTmizer T-Cell growth medium for use in clinical trials. The product was designed to efficiently grow large numbers of potentially therapeutic T-cells, which have indicated promise in clinical studies as an effective treatment for diseases among which include autoimmune disorders, cancer, and infectious diseases such as AIDS.

Don’t Miss: Will New Royalty Rates Cut Costs in Half for Pandora?


More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business